• Limpopo

Free Weekly Newsline Every Friday

Track and Trace the Missing Link in Putting South Africa’s New Cannabis Framework in Place

As cannabis evolves into a commodity with multiple end uses, compliance will have to factor in how the plant – or products derived therefrom - move across various regulatory pathways. H3’s Charl Botha writes that ‘track and trace’ is the missing link needed to sew disparate frameworks together.

South Africa’s cannabis problem is frequently described as a licensing problem, but the difficulty runs considerably deeper than whether a particular operator holds a licence or approval. Several regulatory pathways now deal with cannabis for different purposes, yet those pathways do not form a single commercial system capable of showing where a product originated, under what authority it was produced, which regulatory regime applies to it and whether it remained within that regime as it moved through the market.

The Department of Trade, Industry and Competition’s current work on track-and-trace is therefore more relevant to the cannabis debate than may initially appear. On 9 November 2026, the DTIC published a discussion document on proposed track-and-trace regulations directed at illicit trade in tobacco, alcohol, pharmaceuticals, food and consumer appliances. Cannabis is not identified among the categories presently covered by the document. The significance lies instead in the regulatory approach: products should be identifiable, their origin and movement should be capable of verification, and regulators should have reliable information with which to distinguish legitimate trade from activity taking place outside the authorised chain.

That approach speaks directly to a weakness in South Africa’s cannabis framework because the country did not create one integrated cannabis market. The Constitutional Court’s 2018 judgment protected adult use, possession and cultivation in private, and the Cannabis for Private Purposes Act subsequently provided a statutory framework for private activity. The Department of Justice has expressly stated that neither the judgment nor the Act created a general right to buy or sell cannabis and that commercial cultivation, buying and selling, together with the recognition of traditional growers, fall outside that legislation. Medicinal cannabis operates separately under the Medicines and Related Substances Act and SAHPRA oversight, while hemp cultivation follows an agricultural route.

The difficulty is therefore not that South Africa has no cannabis regulation. It has several forms of regulation developed for different purposes, but the legal and operational connections between them remain incomplete. Medical cannabis must satisfy requirements appropriate to medicines; agricultural production raises different regulatory concerns; private-use rights arise from a different constitutional and statutory foundation; and any future commercial adult-use market will require its own rules around product safety, age restrictions, consumer protection, testing, packaging, taxation and lawful market access. Treating all of those activities as though they are the same would be poor regulation, but leaving them disconnected has created its own problems.

The present controversy around Section 21 illustrates those problems particularly clearly. SAHPRA’s own guideline defines Section 21 as a mechanism through which access may be obtained to unregistered medicines for human use under the Medicines and Related Substances Act and regulation 29. Its purpose is therefore medical access to unregistered medicines, with the regulatory controls that accompany such access, rather than the creation of a general commercial cannabis market.

Jacqui Ramage, regulatory pharmacist and incoming director of the South African Network of Cannabis Professionals, brought the wider problem into sharp focus in her 13 November article for Cannabiz Africa. Her central argument is that the difficulties now associated with Section 21 cannot sensibly be addressed in isolation from the broader cannabis framework. She describes a sector in which substantial private investment has been directed into medicinal cultivation and pharmaceutical compliance while shops, clubs and other grey-market models have expanded in an environment where the route to a general lawful adult-use market remains unresolved.

Some of Ramage’s observations concerning SAHPRA’s recent treatment of Section 21 applications, inspection capacity and particular market practices remain her assessment of the position and should be treated as such unless confirmed by the regulator. Her broader diagnosis, however, sits comfortably with the legal structure already acknowledged by government. South Africa has private-use rights, a regulated medical pathway and an agricultural regime, while ordinary commercial adult-use supply remains outside the Cannabis for Private Purposes Act. The resulting pressure is therefore unlikely to be solved simply by tightening one approval mechanism while leaving the wider market architecture unfinished.

A cannabis product may, for example, have originated within a properly regulated medicinal cultivation environment, but proof of lawful origin does not settle every question that arises later in the chain. Regulators still need to establish whether that product remained within the medicinal pathway, whether its manufacture, distribution and supply were authorised and whether the eventual transaction fell within the authority originally relied upon. The same principle applies on the private-use side, where lawful possession or cultivation for private purposes does not in itself create a general commercial retail right.

Traceability becomes useful once those legal distinctions have been defined, because a properly designed system can give practical effect to them. Provenance, regulatory status and product movement could then be verified across the chain, allowing authorities to identify when a product remains within an authorised pathway and when it has moved into a market for which the original authority was never intended.

The commercial consequences are significant. Operators that invest in pharmaceutical, agricultural, quality-control and governance requirements carry costs that activity outside those systems may not bear. Ramage’s description of medicinal-sector investment occurring alongside a growing informal or grey market illustrates why the problem is broader than enforcement against individual shops or operators. A regulatory framework that places increasingly detailed obligations on compliant businesses while remaining unable to distinguish compliant supply from diversion further down the chain risks penalising the very participants formalisation is intended to encourage.

Traceability must nevertheless be proportionate to the activity being regulated. South Africa has repeatedly spoken about bringing traditional, indigenous and smaller growers into the formal cannabis economy, and a national system designed around the administrative capacity and cost base of large pharmaceutical or vertically integrated businesses could exclude many of those participants before formalisation begins. Medicinal products should remain subject to controls appropriate to medicines, while agricultural and future adult-use activity should carry requirements appropriate to their own risks and purposes. The common regulatory requirement should be the ability to demonstrate lawful origin, accountable movement and the status under which the product is being handled.

The same reasoning applies institutionally. Cannabis already touches health regulation, agriculture, trade and industrial policy, taxation, consumer protection and law enforcement. The recent agreement between SARS and the National Consumer Commission on their respective track-and-trace processes is significant because the two bodies expressly recognised the need to align technical standards, information-sharing, governance and enforcement arrangements while avoiding duplication and unnecessary compliance costs. Cannabis requires comparable coordination, even if responsibility remains distributed among existing regulators rather than being transferred to a single new authority.

These concerns did not arise for the first time with the present Section 21 debate, Ramage’s analysis or the DTIC’s November track-and-trace proposal. During 2026, formal submissions and policy papers placed before government and Parliament argued for controlled participation, traceability, auditable supply chains, coordinated regulatory oversight and evidence-based pilot implementation as practical ways of addressing the gap between the existing cannabis pathways. The recurring concern was that private-use rights, medicinal regulation, agricultural production and future commercial participation would remain difficult to administer while each continued to develop largely within its own regulatory silo.

Controlled pilots provide a practical means of testing proposed models before national implementation, allowing government to establish what information regulators genuinely require, where administrative burdens become disproportionate, how products move between regulatory environments and whether the compliance model remains commercially workable before significant public and private resources are committed.

A properly structured pilot can also test regulatory outcomes while protecting legitimate private interests in data, intellectual property and proprietary methodologies. South African businesses, professionals and compliance specialists have already invested substantial resources in developing governance, traceability, quality-control and compliance systems in response to the uncertainty of the existing market. Government should be able to evaluate whether those approaches work without requiring every element of the underlying methodology to be placed in the public domain as a precondition for consideration.

Ramage’s analysis reinforces a concern that had already been placed before policymakers: the present difficulties are structural and are unlikely to be resolved by concentrating on one regulator, one approval mechanism or one category of operator. The DTIC’s move towards track-and-trace in other high-risk markets now creates an opportunity to move the cannabis discussion beyond repeated diagnosis and towards a regulatory model capable of distinguishing lawful participation from diversion while preserving the different purposes of the existing pathways.

South Africa should therefore resist simply adapting a tobacco or pharmaceutical tracking system and imposing it on cannabis. The task now is to define lawful participation across private, medicinal, agricultural and future commercial activity, determine what information is genuinely necessary to verify compliance and test that architecture through controlled implementation before committing to a national system.

If government follows that sequence, traceability could become more than another administrative obligation. It could provide the practical connection between regulatory systems that currently operate alongside one another, giving legitimate participants a clearer means of demonstrating compliance while allowing regulators to identify more precisely where products leave an authorised chain.

The missing link is therefore not another licence in isolation, nor another regulatory pathway operating beside those that already exist. It is an architecture that connects lawful authority to an accountable supply chain and allows regulators, businesses and consumers to distinguish products that remain within an authorised system from those that have moved outside it.

Charl Botha, B.Proc (S.A.), is a South African regulatory strategist and co-founder of H3 Legal Solutions. He has participated in parliamentary and government engagements concerning cannabis regulation, commercialisation and lawful participation.

Share this post
The Cannabiz Africa Briefing

One weekly email. Everything moving in African cannabis.

"*" indicates required fields

Name*

Search news, companies, regulations

Start typing below to search Cannabiz Africa.